Keyphrases
Adjuvant Therapy
25%
Breast Cancer
25%
Cancer Cells
25%
Cancer Treatment
25%
Clinical Application
100%
Clinical Pathological Characteristics
25%
Detection Rate
25%
Driver mutations
25%
Drug Target
25%
ErbB2
25%
Genetic Modification
100%
Locally Advanced
25%
Mammalian Target of Rapamycin (mTOR)
25%
Metastasis
25%
Metastatic Breast Cancer
100%
Metastatic Tumor
25%
Mitogen-activated Protein Kinase
25%
Molecular Profile
25%
Molecular Targets
25%
Mutated Genes
25%
Optimal Treatment
50%
Predictive Biomarker
25%
Primary Breast Cancer
25%
Primary Tumor
100%
Standard of Care
25%
Subsequent Therapy
25%
Survival Benefit
25%
Targeted Treatment
25%
Treatment Choice
25%
Treatment Resistance
100%
Tumor
25%
Tumor Tissue
25%
Working Diagnosis
25%
Medicine and Dentistry
Adjuvant Therapy
25%
Biological Marker
25%
Breast Cancer
50%
Cancer Cell
25%
Cancer Therapy
25%
Empirical Treatment
25%
Mammalian Target of Rapamycin
25%
MAPK Signaling
25%
Metastatic Breast Cancer
100%
Metastatic Carcinoma
50%
Neoplasm
25%
Primary Tumor
100%
Recurrent Disease
50%
Signal Transduction
25%
Targeted Therapy
25%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Mammalian Target of Rapamycin
100%
MAPK Signaling
100%
Mutated Genes
100%
Signal Transduction
100%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
25%
Breast Cancer
50%
Malignant Neoplasm
50%
Metastasis
25%
Metastatic Breast Cancer
100%
Neoplasm
25%
Primary Tumor
100%
Recurrent Disease
50%